Drug intelligence / Profile preview

calcipotriol + hydrocortisone

Development stage: Phase 3
Lead developer: LEO Pharma
Modality: Small Molecules
Administration: Topical

Overview

Calcipotriol + hydrocortisone is a topical combination drug developed for the treatment of psoriasis. Calcipotriol is a synthetic vitamin D analogue that acts as an agonist at the calcitriol receptor, modulating keratinocyte proliferation and differentiation. Hydrocortisone is a glucocorticoid that acts as an agonist at the glucocorticoid receptor, providing anti-inflammatory effects by inhibiting multiple inflammatory pathways. The combination was designed to leverage both anti-proliferative and anti-inflammatory mechanisms to treat psoriatic lesions[8].

Other names: calcipotriol/hydrocortisone

Targets

GR (Glucocorticoid receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on calcipotriol + hydrocortisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on calcipotriol + hydrocortisone.

Explore the full profile